SEC Form 4 · accession 0001209191-18-025047
AERIE PHARMACEUTICALS INC · AERI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vicente Anido Jr.
Officer — Chief Executive Officer · Director
Period of report
Apr 12, 2018
Accepted (ET)
Apr 16, 2018 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001337553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 12, 2018 | A | 21,448 | $0.00 | A | 133,926 | D | |
| Common Stock | Apr 12, 2018 | F | 3,149 | $53.40 | D | 130,777 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction includes (i) 10,724 shares of common stock that vested on April 12, 2018 and (ii) 10,724 shares of common stock that will vest on April 12, 2019, subject to the reporting person's continued employment with the issuer through such date, pursuant to, in the case of each of clauses (i) and (ii), the issuer's compensation committee having determined that the requisite performance condition (the approval and launch of Rhopressa prior to September 30, 2018) has been achieved.